Ontada Enhances Oncology Care with Research Insights and Tools

Ontada's Contribution to Real-World Oncology Research

At the forefront of oncology advancements, Ontada, a part of McKesson Corporation, is poised to showcase its significant contributions at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. Ontada specializes in real-world data and evidence, clinical education, and technologies that enhance patient care in cancer treatment. This event marks an important occasion for Ontada as it presents groundbreaking research and introduces two innovative solutions aimed at improving cancer outcomes.

Groundbreaking Research Presentations at ASH

During this year's ASH conference, which brings together experts from around the world, Ontada will deliver insights through nine abstracts. Focused on the application of innovative therapies in community oncology settings, these presentations will illuminate the essential role real-world research plays in developing cancer treatments.

The Importance of Real-World Data

According to Dr. Ira Zackon, MD, Senior Medical Director for Ontada, conducting real-world research within community settings is vital. These retrospective studies help determine the efficacy of various cancer treatments, support value-based care initiatives, inform clinical development, and heighten the overall understanding of established care standards.

Research Topics Covered

The research showcased will cover pivotal indications such as Myelofibrosis, Multiple Myeloma, Chronic Lymphocytic Leukemia (CLL), and Chronic Myeloid Leukemia (CML), all treated within community oncology environments. Dr. Zackon will collaborate with Lisa Herms, PhD, to present two key posters that highlight critical findings relating to the use and outcomes of advanced therapies.

Notable Posters Presentation

1. Poster #2410: Real-World Utilization of Bispecific Antibodies for Treatment of Relapsed/Refractory Multiple Myeloma in the US Community Oncology Setting
   • This study investigates characteristics and treatment patterns among 564 adult patients with relapsed/refractory Multiple Myeloma, focusing on those treated with bispecific antibodies compared to those who received extensive prior therapies.
2. Poster #3094: Trends in Real-World Characteristics and Outcomes of Patients with Diffuse Large B-Cell Lymphoma Treated in the US Community Oncology Setting Pre- and Post-CAR-T Approvals
   • This research analyzes trends among over 15,000 patients with Diffuse Large B-Cell Lymphoma, shedding light on how CAR-T approvals have influenced treatment in community settings.

New Solutions for Improved Patient Care

Ontada is proud to present two new data solutions built upon their real-world data platform, ON.Genuity. ON.Sight allows for rapid, data-driven decisions in community oncology, while ON.Path offers real-time insights into clinical workflows, aiding in the optimization of commercial strategies. These tools empower providers to enhance patient journeys by leveraging comprehensive oncology data, including treatment pathways and genomic information.

Experience the New Solutions at ASH

Attendees at ASH are invited to visit Ontada's booth to see demonstrations of ON.Sight and ON.Path solutions, gaining first-hand experience of how these innovations can streamline oncology care.

Commitment to Oncology Excellence

Ontada stands out as part of McKesson’s broader commitment to advancing oncology and specialty solutions. By generating impactful real-world data and evidence, Ontada plays a crucial role alongside McKesson's extensive portfolio in addressing complexities in cancer care and enhancing patient treatment options.

Participating in groundbreaking research and educational initiatives like ASH not only reinforces Ontada's dedication but also their role in driving forward the future of cancer care, connecting cutting-edge therapies with those who need them most.

Frequently Asked Questions

What is Ontada's primary focus at the ASH 2024 Annual Meeting?

Ontada's main focus will be on presenting real-world research findings and introducing two innovative solutions designed to improve oncology care.

Who is Dr. Ira Zackon, and what is his role?

Dr. Ira Zackon is the Senior Medical Director for Ontada, and he emphasizes the importance of real-world research in demonstrating the value of cancer treatments.

What are some key research topics presented by Ontada?

Key topics include Myelofibrosis, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia, focusing on treatments in community settings.

What are ON.Sight and ON.Path?

ON.Sight is a data solution for quick decision-making, while ON.Path provides clinical workflow insights to improve commercial strategies in oncology.

How does Ontada contribute to enhancing cancer care?

Ontada enhances cancer care by providing real-world data and evidence, which informs treatment decisions and helps improve patient outcomes.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.